Does the use of Renin-Angiotensin System antagonists reduce all-cause mortality in patients with heart failure and preserved ejection fraction?
The use of RAS antagonists may be associated with a survival benefit in patients with heart failure and preserved ejection fraction.
Among patients with heart failure and preserved ejection fraction, the use of RAS antagonists was associated with lower all-cause mortality.
Lund et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: